

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{Box}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Seresto 4.50 g + 2.03 g, collar for dogs > 8 kg
Imidacloprid
Flumethrin

2. STATEMENT OF ACTIVE SUBSTANCES

One collar contains:
4.5 g Imidacloprid, 2.03 g Flumethrin

3. PHARMACEUTICAL FORM

Grey, odour free collar

4. PACKAGE SIZE

1 x 70 cm collar
2 x 70 cm collar

5. TARGET SPECIES

Dogs

6. INDICATION(S)

Kills ticks, fleas and lice and repels ticks (“anti-feeding”). Indirect protection against transmission of canine vector-borne disease pathogens (e.g. *leishmaniosis*, *ehrlichiosis*, *babesiosis*). 7 - 8 months protection. Water resistant product.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Keep the bag with the collar in the outer box until use.

10. EXPIRY DATE

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only
[Prescription status to be completed nationally; Blue Box]

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Elanco Europe Ltd.
Form 2, Bartley Way
Bartley Wood Business Park
Hook
RG27 9XA
United Kingdom

16. MARKETING AUTHORISATION NUMBER(S)

Vm 00879/4162

17. MANUFACTURER’S BATCH NUMBER

Lot {number}

Pictograms:



PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{Outer carton, pack size of 12 collars}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Seresto 4.50 g + 2.03 g, collar for dogs > 8 kg
Imidacloprid
Flumethrin

2. STATEMENT OF ACTIVE SUBSTANCES

One collar contains:
4.5 g Imidacloprid, 2.03 g Flumethrin

3. PHARMACEUTICAL FORM

Grey, odour free collar

4. PACKAGE SIZE

12 x 70 cm collar

5. TARGET SPECIES

Dogs

6. INDICATION(S)

Kills ticks, fleas and lice and repels ticks ("anti-feeding"). Indirect protection against transmission of canine vector-borne disease pathogens (e.g. *leishmaniosis*, *ehrlichiosis*, *babesiosis*). 7 - 8 months protection. Water resistant product.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.
Keep the bag with the collar in the outer box until use.

10. EXPIRY DATE

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only
[Prescription status to be completed nationally; Blue Box]

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Elanco Europe Ltd.
Form 2, Bartley Way
Bartley Wood Business Park
Hook
RG27 9XA
United Kingdom

16. MARKETING AUTHORISATION NUMBER(S)

Vm 00879/4162

17. MANUFACTURER’S BATCH NUMBER

Lot {number}

Pictograms:



PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
{Bag}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Seresto 4.50 g + 2.03 g, collar for dogs > 8 kg

2. STATEMENT OF ACTIVE SUBSTANCES

4.5 g Imidacloprid, 2.03 g Flumethrin per collar

3. PHARMACEUTICAL FORM

Collar *[as part of the name]*

4. PACKAGE SIZE

1x 70 cm

5. TARGET SPECIES

Dogs *[as part of the name]*

6. INDICATION(S)

[flea, larvae, tick, louse by pictograms]

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Cutaneous use.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only.
[Prescription status to be completed nationally; Blue Box]

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Elanco Europe Ltd.
Form 2, Bartley Way
Bartley Wood Business Park
Hook
RG27 9XA
United Kingdom

16. MARKETING AUTHORISATION NUMBER(S)

Vm 00879/4162

17. MANUFACTURER’S BATCH NUMBER

Lot

Pictograms as mentioned above:



B. PACKAGE LEAFLET

PACKAGE LEAFLET

Seresto 4.50 g + 2.03 g, collar for dogs > 8 kg

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Elanco Europe Ltd.
Form 2, Bartley Way
Bartley Wood Business Park
Hook
RG27 9XA
United Kingdom

Manufacturer responsible for batch release:

KVP Pharma + Veterinär Produkte GmbH
Projensdorfer Str. 324, 24106 Kiel
Germany

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Seresto 4.50 g + 2.03 g, collar for dogs > 8 kg
Imidacloprid
Flumethrin

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

One grey, odour free collar of 70 cm (45 g) contains 4.5 g imidacloprid and 2.03 g flumethrin as active substances.

4. INDICATION(S)

For the treatment and prevention of flea (*Ctenocephalides felis*, *C. canis*) infestation for 7 to 8 months.

Protects the animal's immediate surroundings against flea larvae development for 8 months.

Seresto can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

The product has persistent acaricidal (killing) efficacy against tick infestations (*Ixodes ricinus*, *Rhipicephalus sanguineus*, *Dermacentor reticulatus*) and repellent (anti-feeding) efficacy against tick infestations (*Ixodes ricinus*, *Rhipicephalus sanguineus*) for 8 months. It is effective against larvae, nymphs and adult ticks. Ticks already on the dog prior to treatment may not be killed within 48 hours after collar application and may remain attached and visible. Therefore removal of ticks already on the dog at the time of application is recommended. The prevention of infestations with new ticks starts within two days after application of the collar.

For treatment of biting/chewing lice (*Trichodectes canis*) infestation.

The product provides indirect protection against the transmission of the pathogens *Babesia canis vogeli* and *Ehrlichia canis* from the tick vector *Rhipicephalus sanguineus*, thereby reducing the risk of canine babesiosis and canine ehrlichiosis for 7 months.

Reduction of the risk of infection with *Leishmania infantum* via transmission by sand flies for up to 8 months.

5. CONTRAINDICATIONS

Do not treat puppies less than 7 weeks of age.

Do not use in case of hypersensitivity to the active substances or to any of the excipients.

6. ADVERSE REACTIONS

In rare cases behavioural disorders that may include hiding, vocalization, hyperactivity, excessive licking and/or grooming or scratching at the application site may be observed in animals that are not used to wearing collars on the first few days after fitting. Aggression after collar application was reported in very rare cases. Ensure that the collar is fitted correctly.

Application site reactions such as pruritus, erythema and hair loss may occur. These have been reported as rare and usually resolve within 1 to 2 weeks. In single cases, a temporary collar removal may be recommended until the symptoms have disappeared.

In very rare cases, application site reactions such as dermatitis, inflammation, eczema, lesions or haemorrhage may occur and in these instances, collar removal is recommended.

In rare cases neurological symptoms as ataxia, convulsions and tremor may occur.

In these

cases collar removal is recommended.

Also in rare cases in dogs, slight and transient reactions as depression, change of food intake, salivation, vomiting and diarrhea might occur initially.

The frequency of adverse reactions is defined using the following convention:

-very common (more than 1 in 10 animals treated displaying adverse reaction(s))

-common (more than 1 but less than 10 animals in 100 animals treated)

-uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

-rare (more than 1 but less than 10 animals in 10,000 animals treated)

-very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs


8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Dogs above 8 kg receive one collar of 70 cm length.
Small dogs up to 8 kg receive one collar of 38 cm length.

Cutaneous use. One collar per animal to be fastened around the neck. For external use only.

9. ADVICE ON CORRECT ADMINISTRATION

Remove collar from protective bag directly before use. Unroll collar and make sure that there are no remnants from the plastic connectors inside the collar. Adjust the collar around the animal's neck without tightening it too tight (as a guide, it should be possible to insert 2 fingers between the collar and the neck). Pull excess collar through the loop and cut off any excess length extending beyond 2 cm.



The collar should be worn continuously for the 8 month protection period and should be removed after the treatment period. Check periodically and adjust fit if necessary, especially when puppies are rapidly growing.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use after expiry date stated on the bag and outer box. The expiry date refers to the last day of that month.

12. SPECIAL WARNING(S)

Special warnings for each target species:

Ticks will be killed and fall off the host within 24 to 48 hours after infestation without having had a blood meal, as a rule. An attachment of single ticks after treatment cannot be excluded.

For this reason, a transmission of infectious diseases by ticks cannot be completely excluded if conditions are unfavourable. Ideally, the collar should be applied before the beginning of the flea or, tick season.

Although a significant reduction in the incidence of infection with *Leishmania infantum* in dogs has been demonstrated, the product has shown variable repellent

(anti-feeding) and insecticidal efficacy against the sand fly *Phlebotomus perniciosus*. As a result, bites by sand flies may occur, and the transmission of *Leishmania infantum* cannot be completely excluded. The collar should be applied just before the beginning of the period of activity of sand fly vectors corresponding to the *Leishmania infantum* transmission season and worn continuously throughout the risk period.

As in all longterm topical products, periods of excessive seasonal hair shedding may lead to transient slight reduction of efficacy by loss of hair-bound portions of the active ingredients. Replenishment from the collar starts immediately so that full efficacy will be re-established without any additional treatment or collar replacement.

For optimum control of flea problems in heavily infested households it may be necessary to treat the environment with a suitable insecticide.

The product is water resistant; it remains effective if the animal becomes wet. However, prolonged, intense exposure to water or extensive shampooing should be avoided as the duration of activity may be reduced. Studies show that monthly shampooing or water immersion does not significantly shorten the 8 months efficacy duration for ticks after redistribution of the active substances in the coat whereas the product's flea efficacy gradually decreased, starting in the 5th month. The influence of shampooing or water immersion regarding the transmission of canine leishmaniosis has not been examined.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Keep the bag with the collar in the outer packaging until use.

As with any veterinary medicinal product, do not allow small children to play with the collar, or to put it into their mouths. Pets wearing the collar should not be allowed to sleep in the same bed as their owners, especially children. Imidacloprid and flumethrin are continuously released from the collar to the skin and fur whilst the collar is being worn.

The product may cause hypersensitivity reactions in some people.

People with known hypersensitivity (allergy) to the ingredients of the collar should avoid contact with the veterinary medicinal product.

The product may cause skin, eye and respiratory irritation in some people in very rare cases. In case of eye irritation, flush eyes thoroughly with cold water. In case of skin irritation, wash the skin with soap and cold water. If symptoms persist it is recommended to seek medical advice and show the package leaflet or the label to the physician.

Immediately dispose of any remnants or cut-offs of the collar (see section "advice on correct administration").

Wash hands with cold water after fitting the collar.

Pregnancy, lactation, Lay:

Laboratory studies with either flumethrin or imidacloprid in rats and rabbits have not produced any effects on fertility or reproduction and showed no teratogenic, or foetotoxic effects. However, the safety of the veterinary medicinal product has not been established in target animals during pregnancy and lactation and in the absence of available data, the product is therefore not recommended in pregnant and lactating bitches.

Overdose (symptoms, emergency procedures, antidotes):

Due to the nature of the collar overdosage is unlikely and signs of overdosage are not to be expected.

An overdosage of 5 collars around the neck was investigated in adult dogs for an 8 months period and in 7 week old puppies for a 6 months period and no adverse effects were observed besides slight hair loss and mild skin reactions.

In the unlikely event of the animal eating the collar mild gastrointestinal symptoms (e.g. loose stool) may occur.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

This product should not enter water courses as it may be dangerous for fish and other aquatic organisms.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

October 2020

15. OTHER INFORMATION

Pack sizes: box containing one or two collars; carton containing 12 collars.
Not all pack sizes may be marketed.

Both active ingredients are slowly and continuously released in low concentrations from the polymer matrix system of the collar towards the animal. Both actives are present in the dog's haircoat in acaricidal/insecticidal concentrations during the entire efficacy period. The active substances spread from the site of direct contact over the entire skin surface. Target animal overdose and serum kinetic studies have established that imidacloprid reached the systemic circulation transiently while flumethrin was mostly not measurable. Oral absorption of both active substances is not relevant for the clinical efficacy.

Efficacy against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*) starts within 48 hours after application of the collar. In addition to the indications listed above an activity against *Pulex irritans* has been demonstrated.

In addition to the tick species listed above activity has been demonstrated against *Ixodes hexagonus*, *I. scapularis* and the non-European tick species *Dermacentor variabilis* and the Australian paralysis tick *I. holocyclus*.

The product provides repellent (anti-feeding) activity against the claimed ticks, thus preventing repelled parasites from taking a blood meal and thereby indirectly aids in the reduction of the risk of Canine Vector-Borne Disease transmission.

In addition to the pathogens listed under indications, indirect protection against the transmission of *Babesia canis canis* (by *Dermacentor reticulatus* ticks) has been shown in one laboratory study at day 28 after treatment, and indirect protection against the transmission of *Anaplasma phagocytophilum* (by *Ixodes ricinus* ticks) has been shown in one laboratory study at 2 months after treatment, thereby reducing the risk of diseases caused by these pathogens under the conditions of these studies.

Data from efficacy studies against sand flies (*Phlebotomus perniciosus*) showed a variable sand fly repellent (anti-feeding) efficacy ranging from 65 to 89% for 7-8 months following initial application of the collar. Data from 3 clinical field studies performed in endemic areas indicate a significant reduction in the risk of *Leishmania infantum* transmission by sand flies in treated dogs compared to non-treated dogs. Depending on the infection pressure by sand flies the efficacy in the reduction of the risk of infection with leishmaniosis ranged from 88.3 to 100%.

The collars were able to improve the *Sarcoptes scabiei* infestation in pre-infested dogs leading to a full cure after three months.

Approved 02 October 2020

A handwritten signature in black ink, appearing to read "A. Hunter.", positioned below the approval date.